Back to Clinical Trials

Brief Title: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

INTRODUCTION

  • Org Study ID: D910PC00001
  • Secondary ID: N/A
  • NTC ID: NCT04960709
  • Sponsor: AstraZeneca

BRIEF SUMMARY

A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer.

The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC).

Volga trial consists of two parts: Safety Run-In and Main Study. In total the study aims to enroll approximately 830 patients, who will receive triplet combination, duplet combination of Durvalumab and Enfortumab vedotin or currently approved SOC in the main trial. In the main part of the trial there is two out of three chances of being on a treatment arm and the treatment is assigned at random by a computer system.

In this trial patients in the two treatment arms will receive either 3 cycles of neoadjuvant Durvalumab + Tremelimumab + Enfortumab Vedotin or Durvalumab + Enfortumab vedotin and after surgery both treatment arms will continue with adjuvant Durvalumab.

DETAILED DESCRIPTION

Not provided

  • Overall Status
    Recruiting
  • Start Date
    August 5, 2021
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Compare efficacy of durvalumab + tremelimumab + EV relative to cystectomy alone on pCR rate (Safety Run-In and Main Study)

Primary Outcome 1 - Timeframe: Up to 3 years

Primary Outcome 2 - Measure: Compare efficacy of durvalumab + tremelimumab + EV relative to cystectomy alone on EFS (Safety Run-In and Main Study)

Primary Outcome 2 - Timeframe: Up to 3 years

Primary Outcome 3 - Measure: Safety and Tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part)

Primary Outcome 3 - Timeframe: At completion of study treatment by the last patient and at 3 months.

Primary Outcome 4 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by vital signs (blood pressure in mmHg) (Safety Run-In part)

Primary Outcome 4 - Timeframe: Up to 84 months

Primary Outcome 5 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by vital signs (pulse rate) in beats per minute (Safety Run-In part)

Primary Outcome 5 - Timeframe: Up to 84 months

Primary Outcome 6 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by vital signs (respiration rate) in breaths per minute (Safety Run-In part)

Primary Outcome 6 - Timeframe: Up to 84 months

Primary Outcome 7 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by vital signs (temperature) in degrees Celsius (Safety Run-In part)

Primary Outcome 7 - Timeframe: Up to 84 months

Primary Outcome 8 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin s assessed by abnormality in clinical chemistry by liver function (Safety Run-In part)

Primary Outcome 8 - Timeframe: Up to 84 months

Primary Outcome 9 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in clinical chemistry by kidney function (Safety Run-In part)

Primary Outcome 9 - Timeframe: Up to 84 months

Primary Outcome 10 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in clinical chemistry by thyroid function (Safety Run-In part)

Primary Outcome 10 - Timeframe: Up to 84 months

Primary Outcome 11 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in haematology (Safety Run-In part)

Primary Outcome 11 - Timeframe: Up to 84 months

Primary Outcome 12 - Measure: Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by ECG (pulse rate) (Safety Run-In part)

Primary Outcome 12 - Timeframe: Up to 84 months

Primary Outcome 13 - Measure: Changes in WHO/ECOG performance status (Safety Run-In part)

Primary Outcome 13 - Timeframe: Up to 84 months

CONDITION

  • Muscle Invasive Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
Histologically or cytologically documented muscle-invasive UC of the bladder.

- Participants with transitional cell and mixed transitional/non-transitional cell histologies;

- Participants with MIBC clinical tumor (T) stage T2-T4aN0/1M0 or UC of the bladder with clinical state T1N1M0.

- Participants should also have not received prior systemic chemotherapy or immunotherapy for the treatment of MIBC or bladder UC.

- Medically fit for cystectomy and able to receive neoadjuvant therapy;

- Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC;

- ECOG performance status of 0,1,2 at enrollment.

- Availability of tumor sample prior to study entry;

- Must have a life expectancy of at least 12 weeks at randomization.

- Cisplatin-ineligible, as defined by any of the following criteria (based on Galsky et al 2011) OR Refuse cisplatin based chemotherapy (must be documented in the medical records)
Exclusion criteria:
Evidence of lymph node (N2+) or metastatic TCC/UC disease at the time of screening.

- Active infection

- Uncontrolled intercurrent illness

- Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other anti-CTLA-4, anti--PD-1, anti PD-L1, or anti-PD-L2 antibodies.

- Current or prior use of immunosuppressive medication within 14 days before the first dose of IPs.

Gender: All

Minimum Age: 18 Years

Maximum Age: 130 Years

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: N/A

Phone: 1-877-240-9479

Email: information.center@astrazeneca.com

LOCATION

Facility Status Contact
Facility: Research Site
Orange, California 92868
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Santa Monica, California 90404
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Colorado Springs, Colorado 80909
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Washington, District of Columbia 20010
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Coeur d'Alene, Idaho 83814
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Brighton, Michigan 48114
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Detroit, Michigan 48202
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Jackson, Mississippi 39213
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Las Vegas, Nevada 89102
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Saddle Brook, New Jersey 07663
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Brooklyn, New York 11219
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Buffalo, New York 14263
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Syracuse, New York 13210
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Portland, Oregon 97239
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Hershey, Pennsylvania 17033
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Fort Worth, Texas 76104
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Irving, Texas 75063
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Norfolk, Virginia 23502
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Tacoma, Washington 98405
United States
Status: Recruiting Contact: N/A
Facility: Research Site
Caba, Ontario C1280AEB
Argentina
Status: Recruiting Contact: N/A
Facility: Research Site
Ciudad de Buenos Aires, C1419AHL
Argentina
Status: Recruiting Contact: N/A
Facility: Research Site
Pergamino, B2700CPM
Argentina
Status: Recruiting Contact: N/A
Facility: Research Site
Linz, 4020
Austria
Status: Recruiting Contact: N/A
Facility: Research Site
Salzburg, 5020
Austria
Status: Recruiting Contact: N/A
Facility: Research Site
Wien, 1020
Austria
Status: Recruiting Contact: N/A
Facility: Research Site
Santiago, 7500653
Chile
Status: Recruiting Contact: N/A
Facility: Research Site
Santiago, 7500921
Chile
Status: Recruiting Contact: N/A
Facility: Research Site
Amiens, 64100
France
Status: Recruiting Contact: N/A
Facility: Research Site
Bayonne, 33075
France
Status: Recruiting Contact: N/A
Facility: Research Site
Clermont Ferrand, 59000
France
Status: Recruiting Contact: N/A
Facility: Research Site
Lille, 69008
France
Status: Recruiting Contact: N/A
Facility: Research Site
Lyon, 13273
France
Status: Recruiting Contact: N/A
Facility: Research Site
Marseille CEDEX, 13385
France
Status: Recruiting Contact: N/A
Facility: Research Site
Marseille, 34070
France
Status: Recruiting Contact: N/A
Facility: Research Site
Montpellier, 06189
France
Status: Recruiting Contact: N/A
Facility: Research Site
Nice, 31130
France
Status: Recruiting Contact: N/A
Facility: Research Site
Quint-Fonsegrives, 35000
France
Status: Recruiting Contact: N/A
Facility: Research Site
Strasbourg, 92150
France
Status: Recruiting Contact: N/A
Facility: Research Site
Suresnes, 54519
France
Status: Recruiting Contact: N/A
Facility: Research Site
Vandoeuvre les Nancy, 33611
France
Status: Recruiting Contact: N/A
Facility: Research Site
Bielefeld, 44791
Germany
Status: Recruiting Contact: N/A
Facility: Research Site
Düsseldorf, 35392
Germany
Status: Recruiting Contact: N/A
Facility: Research Site
Mannheim, 81377
Germany
Status: Recruiting Contact: N/A
Facility: Research Site
Athens, 12462
Greece
Status: Recruiting Contact: N/A
Facility: Research Site
Athens, 71110
Greece
Status: Recruiting Contact: N/A
Facility: Research Site
Heraklion, 15125
Greece
Status: Recruiting Contact: N/A
Facility: Research Site
Maroussi, Athens, 00000
Greece
Status: Recruiting Contact: N/A
Facility: Research Site
Firenze, 47014
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Meldola, 20132
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Milano, 20141
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Napoli, 35128
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Padova, 80078
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Pozzuoli, 42100
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Roma, 00144
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Roma, 05100
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Terni, 73039
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Verona, 113-8431
Italy
Status: Recruiting Contact: N/A
Facility: Research Site
Bunkyo-ku, 811-1395
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Fukuoka-shi, 431-3192
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Hamamatsu-shi, 036-8563
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Hirosaki-shi, 272-8516
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Ichikawa-shi, 920-8641
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Kanazawa-shi, 634-8522
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Kashihara-shi, 761-0793
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Kita-gun, 650-0017
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Kumamoto-shi, 791-0288
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Matsuyama-shi, 889-1692
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Miyazaki-shi, 700-8558
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Okayama-shi, 541-8567
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Osaka-shi, 545-8586
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Osaka-shi, 589-8511
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Shinjuku-ku, 930-0194
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Toyama-shi, 305-8576
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Yokohama-shi, 47392
Japan
Status: Recruiting Contact: N/A
Facility: Research Site
Busan, 10408
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Goyang-si, 405-760
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Incheon, 03722
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Seodaemun-gu, 13620
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Seongnam-si, 03080
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Seoul, 06351
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Seoul, 07985
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Seoul, 28018
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Research Site
Arnhem, 4818 CK
Netherlands
Status: Recruiting Contact: N/A
Facility: Research Site
Breda, 9713 GZ
Netherlands
Status: Recruiting Contact: N/A
Facility: Research Site
Groningen, 1313 XZ
Netherlands
Status: Recruiting Contact: N/A
Facility: Research Site
Leiden, 3508 GA
Netherlands
Status: Recruiting Contact: N/A
Facility: Research Site
Utrecht, 60-185
Netherlands
Status: Recruiting Contact: N/A
Facility: Research Site
Skórzewo, 02-781
Poland
Status: Recruiting Contact: N/A
Facility: Research Site
Warszawa, 4710
Poland
Status: Recruiting Contact: N/A
Facility: Research Site
Faro, 1350-352
Portugal
Status: Recruiting Contact: N/A
Facility: Research Site
Lisboa, 1500-458
Portugal
Status: Recruiting Contact: N/A
Facility: Research Site
Lisboa, 1500-650
Portugal
Status: Recruiting Contact: N/A
Facility: Research Site
Vila Nova de Gaia, 620102
Portugal
Status: Recruiting Contact: N/A
Facility: Research Site
Barcelona, 08036
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Barcelona, 08041
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Barcelona, 08208
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Barcelona, 08907
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
L'Hospitalet de Llobregat, 35016
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Las Palmas de Gran Canaria, 28033
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Madrid, 28040
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Madrid, 28046
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Madrid, 31008
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Pamplona, 39008
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Santander, 41009
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Sevilla, 40447
Spain
Status: Recruiting Contact: N/A
Facility: Research Site
Taichung, 40705
Taiwan
Status: Recruiting Contact: N/A
Facility: Research Site
Taichung, 70403
Taiwan
Status: Recruiting Contact: N/A
Facility: Research Site
Tainan, 710
Taiwan
Status: Recruiting Contact: N/A
Facility: Research Site
Tainan, 10048
Taiwan
Status: Recruiting Contact: N/A
Facility: Research Site
London, 100000
United Kingdom
Status: Recruiting Contact: N/A
Facility: Research Site
London, 100000
United Kingdom
Status: Recruiting Contact: N/A